US2009069247A1PendingUtilityA1
Use of tight junction antagonists to treat inflammatory bowel disease
Est. expiryOct 6, 2026(~0.2 yrs left)· nominal 20-yr term from priority
A61K 38/08A61P 29/00A61P 1/00A61K 31/56C07K 7/06A61P 1/04A61K 45/06
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.
Claims
exact text as granted — not AI-modified1 . A method of treating inflammatory bowel disease comprising:
administering to a subject in need thereof a composition comprising a tight junction antagonist.
2 . A method according to claim 1 , wherein the antagonist is a peptide.
3 . A method according to claim 2 , wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-24.
4 . A method according to claim 2 , wherein the peptide comprises the sequence
GGVLVQPG.
(SEQ ID NO:15)
5 . A method according to claim 2 , wherein the peptide consists essentially of the sequence
GGVLVQPG.
(SEQ ID NO:15)
6 . A method according to claim 1 , wherein the composition is a delayed release composition.
7 . A method according to claim 1 , wherein the composition comprises a therapeutic agent.
8 . A method according to claim 7 , wherein the therapeutic agent includes one or more agents selected from the group consisting of aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics.
9 . A method according to claim 7 , wherein the therapeutic agent comprises a steroid.
10 . A method of treating Crohn's disease comprising:
administering to a subject in need thereof a composition comprising a tight junction antagonist.
11 . A method according to claim 10 , wherein the antagonist is a peptide.
12 . A method according to claim 11 , wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-24.
13 . A method according to claim 11 , wherein the peptide comprises the sequence
GGVLVQPG.
(SEQ ID NO:15)
14 . A method according to claim 11 , wherein the peptide consists essentially of the sequence
GGVLVQPG.
(SEQ ID NO:15)
15 . A method according to claim 10 , wherein the composition is a delayed release composition.
16 . A method according to claim 10 , wherein the composition comprises a therapeutic agent.
17 . A method according to claim 16 , wherein the therapeutic agent includes one or more agents selected from the group consisting of aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics.
18 . A method according to claim 16 , wherein the therapeutic agent comprises a steroid.
19 . A method of treating ulcerative colitis comprising:
administering to a subject in need thereof a composition comprising a tight junction antagonist.
20 . A method according to claim 19 , wherein the antagonist is a peptide.
21 . A method according to claim 20 , wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-24.
22 . A method according to claim 20 , wherein the peptide comprises the sequence
GGVLVQPG.
(SEQ ID NO:15)
23 . A method according to claim 20 , wherein the peptide consists essentially of the sequence
GGVLVQPG.
(SEQ ID NO:15)
24 . A method according to claim 19 , wherein the composition is a delayed release composition.
25 . A method according to claim 19 , wherein the composition comprises a therapeutic agent.
26 . A method according to claim 25 , wherein the therapeutic agent includes one or more agents selected from the group consisting of aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics.
27 . A method according to claim 25 , wherein the therapeutic agent comprises a steroid.
28 . A method according to claim 1 , wherein the subject is a human.
29 . A method according to claim 1 , wherein the subject is a dog.
30 . A method according to claim 10 , wherein the subject is a human.
31 . A method according to claim 10 , wherein the subject is a dog.
32 . A method according to claim 19 , wherein the subject is a human.
33 . A method according to claim 19 , wherein the subject is a dog.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.